8-K
filed January 24, 2025, 6:59 PM ET
ticker FHTX
CIK 0001822462
regulatory
confidence high
sentiment negative
materiality 0.35
Foghorn Therapeutics receives Nasdaq non-compliance notice over audit committee composition
Foghorn Therapeutics Inc.
- Nasdaq notified Foghorn on Jan 23, 2025 that its audit committee has only two members, violating Listing Rule 5605.
- Vacancy follows resignation of director Adam M. Koppel from board and audit committee effective Dec 29, 2024.
- Cure period runs until earlier of next annual meeting or Dec 29, 2025; if meeting before June 27, 2025, then by June 27, 2025.
- Board intends to appoint a new independent director to fill the audit committee vacancy within the cure period.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001628280-25-002466
- form_type
- 8-K
- ticker
- FHTX
- cik
- 0001822462
- company_name
- Foghorn Therapeutics Inc.
- filed_at
- 2025-01-24T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:05.079079+00:00
- generated_at
- 2026-05-27T11:33:33.422012+00:00
- sec_items
- ["3.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.35
- calibrated_materiality_score
- 0.35
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001628280-25-002466
- json_url
- https://secwatch.observer/filing/0001628280-25-002466.json
- markdown_url
- https://secwatch.observer/filing/0001628280-25-002466.md
- text_url
- https://secwatch.observer/filing/0001628280-25-002466.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/fhtx-20250123.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
LASE
Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q
Laser Photonics Corp
May 22, 2026, 5:27 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee
Comparable filing
received a notice from Nasdaq Listing Qualifications
department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q
for the period ended March 31, 2026, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated
that the Company has 60 days to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception
to allow the Company to regain compliance up to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or
November 16, 2026. A
copy of t
Filing page
SEC filing
INV
Innventure regains Nasdaq compliance after appointing Bruce Brown to Audit Committee
Innventure, Inc.
May 19, 2026, 5:45 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee
Comparable filing
April 30, 2026, following the resignation of Daniel Hennessy from the Company’s Board of Directors (the “Board”) and Audit Committee effective April 29, 2026, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) t
Filing page
SEC filing
ILLR
Triller gets Nasdaq bid-price exception until June 30, 2026
Triller Group Inc.
June 2, 2026, 8:26 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee
Comparable filing
May 29, 2026, the Nasdaq Hearings Panel (the
“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant
Triller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,
2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following
a successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which
modified a previous December 26, 2025 decision by a Nasdaq Hearings Panel
Filing page
SEC filing
ISPC
iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum
iSpecimen Inc.
June 1, 2026, 5:00 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee
Comparable filing
May 29, 2026, iSpecimen Inc. (the “Company”)
received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum
of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report
on Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May
29, 2026, the Company doe
Filing page
SEC filing
GENC
Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing
GENCOR INDUSTRIES INC
June 1, 2026, 4:09 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee
Comparable filing
May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY
Filing page
SEC filing
NUTR
NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026
NUSATRIP Inc
June 1, 2026, 7:10 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee
Comparable filing
May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)
from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s
non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely
file its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended
March 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req
Filing page
SEC filing
XXI
Twenty One Capital receives NYSE non-compliance notice; audit committee lacks independence; cure due June 5
Twenty One Capital, Inc.
June 1, 2026, 7:05 AM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee
Comparable filing
cator
and website references will be removed when the Company regains compliance with all NYSE quantitative and corporate governance listing
standards. The Company expects to appoint, as soon as practicable, an additional member to the audit committee who meets the independence
requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the Listed Company Manual. Forward-Looking Statements Certain statements in this periodic report are “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words indi
Filing page
SEC filing
COLA
Columbus Acquisition regains compliance with Nasdaq $50M MVLS rule; delisting risk removed
Columbus Acquisition Corp/Cayman Islands
May 29, 2026, 9:56 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
This filing
January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee
Comparable filing
May 28, 2026, the Company the Company received a written notice from Nasdaq notifying the Company that the Staff has determined that
for the last 10 consecutive business days, from May 13, 2026 to May 27, 2026, the Company’s MVLS has been $50 million or greater.
Accordingly, the Company has regained compliance with the MVLS Rule and the Staff has indicated that the matter is now closed. 1 SIGNATURES Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. Columbus
Acq
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.